Dramatic Resolution of Pleural Effusion in Children with Chronic Myelomonocytic Leukemia Following Short-course High-dose Methylprednisolone

References

• Byrd J. C., Edenfield W. J., Dow N. S., Aylesworth C., Dawson N. Extramedullary myeloid cell tumors in myelodysplastic-syndromes: Not a true indication of impending acute myeloid leukemia. Leuk, Lymph. 1996; 21: 153–159
   PubMed Web of Science ®Google Scholar
• List A. F., Gonzalez-Osete G., Kummet T., Doll D. C. Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration. Am. J. Med. 1991; 90: 274–276
   PubMed Web of Science ®Google Scholar
• Da Silva M. A. P., Moriarty A., Schultz S., Tricot G. Extra-medullary disease in myelodysplastic syndromes. Am. J. Med. 1988; 85: 589–590
   PubMed Web of Science ®Google Scholar
• Mufti G. J., Oscier D. G., Hamblin T. J., Nightingale A., Darlow S. Serous effusions in monocytic leukemias. Br. J. Haematol 1994; 58: 547–552
   Web of Science ®Google Scholar
• Manoharan A. Malignant pleural effusion in chronic myelomonocytic leukemia. Thorax 1991; 46: 461–462
   PubMed Web of Science ®Google Scholar
• Matsushima T., Murakami H., Kim K., Uchiumi H., Muraba N., Tamura J., Sawamura M., Karasawa M., Naruse T., Tsuchiya J. Steroid-responsive pulmonary disorders associated with myelodysplastic syndromes with der (1q;7p) chromosomal abnormality. Am. J. Hematol 1995; 50: 110–115
   PubMed Web of Science ®Google Scholar
• HiÇsönmez G., Kale G., Erdem G., BilgiÇ S., Hazar V. Dramatic effect of high-dose methylprednisolone on orbital granulocytic sarcoma. Pediatr. Hematol. Oncol. 1996; 13: 187–190
   PubMed Web of Science ®Google Scholar
• HiÇsönmez G., ÖZsoylu Ş., Tuncer A. M. Differentiation of myeloid leukemic cells induced by high-dose methylprednisolone in patients with acute myeloblastic leukemia and its therapeutic potential. Leuk. Res. 1991; 15: 537–541
   PubMed Web of Science ®Google Scholar
• HiÇsönmez G., ÖZsoylu Ş., Tuncer A. M., ErtÜRk G., ÖZbek N., Karadeniz N. Direct morphologic evidence of high-dose methylprednisolone-induced maturation of leukemic cells in children with acute non-lymphoblastic leukemia. Exp. Hematol 1991; 19: 232–233
   PubMed Web of Science ®Google Scholar
• HiÇsönmez G., Tuncer A. M., GÜLer E., Tan E., Tekeüoglu M. The potential role of high-dose methylprednisolone on the maturation of leukemic cells in children with acute promyelocytic leukemia (APL). Exp. Hematol. 1993; 21: 599–601
   PubMed Web of Science ®Google Scholar
• HiÇsönmez G., Tuncer A. M., ÇEtin M., GÜMrÜK F., Kara A., Yalçin S. Morphologic evidence of in vivo differentiation in acute myeloblastic leukemia. Acta Haematol. 1993; 90: 214–215
   PubMed Web of Science ®Google Scholar
• HiÇsönmez G., Erdemli E., Tekeliolu M., Tuncer A. M., ÖZbek N., ÇEtin M., Cotter T. G. Morphologic evidence of apoptosis in childhood acute myeloblastic leukemia treated with high-dose methylprednisolone. Leuk. Lymph. 1996; 22: 91–96
   PubMed Web of Science ®Google Scholar
• Lotem J., Sachs L. Induction of specific changes in the surface membrane of myeloid leukemic cells by steroid hormones. Int. J. Cancer. 1975; 15: 731–740
   PubMed Web of Science ®Google Scholar
• Blewitt R. W., Abbott A. C., Bird C. C. Mode of cell death induced in human lymphoid cells by high and low doses of glucocorticoid. Br. J. Cancer 1983; 47: 477–486
   PubMed Web of Science ®Google Scholar
• HiÇsönmez G., Karadeniz N., Zamani V. P., Tuncer A. M., GÜMriik F., ErtÜRk G., GÜRgey A., özsoylu Ş. High remission rate in acute myeloblasts leukemia in children treated with high-dose methylprednisolone. Eur. J. Haematol. 1992; 48: 215–220
   PubMed Web of Science ®Google Scholar
• HiÇsönmez G., Tuncer A. M., Sayli T., GÜLer E., ÇEtin M., ÖZbek N., Mufti G. J. High-dose methylprednisolone, low-dose cytosine arabinoside and mitoxantrone in children with myelodysplastic syndromes. Hematol. Pathol. 1995; 9: 185–193
   PubMedGoogle Scholar
• HiÇsönmez G., ÖZsoylu Ş., GÜRgey A., Zamani V. P., Irken G. High-dose methylprednisolone for remission induction in children with acute non-lymphoblastic leukemia. Eur. J. Haematol. 1989; 42: 498–500
   PubMed Web of Science ®Google Scholar
• Thomas X., Fiere D., Archimbaud E. Persistence of retinoic acid sensitivity in relapsed acute promyelocytic leukemia with extramedullary involment. Leukemia 1994; 8: 520–521
   PubMed Web of Science ®Google Scholar
• Brown D. M., Kimura A. E., Ossoing K. C., Weiner G. J. Acute promyelocytic infiltration of the optic nerve treated by oral trans-retinoic acid. Ophtalmalogy 1992; 99: 1463–1467
   PubMed Web of Science ®Google Scholar
• Lederman C. A., Weisberger J., Seiter K., Feldman E. J. Differentiation of extramedullary acute promyelocytic leukemia by all-trans retinoic acid. Leuk. Lymph. 1995; 18: 189–193
   PubMed Web of Science ®Google Scholar
• Hasle H., Jacobsen B. B., Pedersen N. T. Myelodysplastic syndromes in childhood: A population based study of nine cases. Br. J. Haematol. 1992; 81: 495–498
   PubMed Web of Science ®Google Scholar
• Nagler A., Hazani A., Etzioni A., Tatarsky I. Disturbances of T-lymphocyte subsets preceding refractory anemia with excess blasts in transformation in a child. Acta Haematol. 1988; 79: 103–106
   PubMed Web of Science ®Google Scholar
• Bagby G. C., Gabourel J. D., Unman J. W. Glucocorticoid therapy in the preleukemic syndrome(Hemopoietic Dysplasia): identification of responsive patients using in-vitro techniques. Ann. Intern. Med. 1980; 92: 55–58
   PubMed Web of Science ®Google Scholar
• Prystowsky J. H., Johnson B. L., Bolwell B. J., Lazarus G. S. Treatment of cutaneous granulocytic sarcoma in a patient with myelodysplasia. Am. J. Med. 1989; 86: 477–480
   PubMed Web of Science ®Google Scholar
• Motoji T., Teramura M., Takahashi M., Oshimi K., Okada M., Kasukabe K., Mizoguchi H. Successful treatment of refractory anemia with high-dose methylprednisolone. Am. J. Hematol. 1990; 33: 8–12
   PubMed Web of Science ®Google Scholar
• Imai Y., Fukuoka T., Nakatani A., Ohsaka A., Takahashi A. Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodyplastic syndrome following combination therapy with cytokines (granulocyte colony stimulating factor and erythropoietin) and high-dose methylprednisolone. Br. J. Haematol. 1996; 93: 146–150
   PubMed Web of Science ®Google Scholar